with medical treatment alone therefore seems the most appropriate management of patients with SCAD who become asymptomatic with medical treatment and who do not show any evidence of ongoing ischaemia or haemodynamic instability. Revascularisation seems only warranted in cases of recurrent anginal symptoms and should be considered when, after prolonged medical treatment, a pronounced dissection persists in a major coronary artery causing a marked and extensive inducible myocardial ischaemia upon myocardial perfusion imaging.

Christian J M Vrints

Correspondence to Christian J M Vrints, University of Antwerp/University Hospital, Wijnikstraat 10, Edegem 2650, Belgium; christian.j.vrints@ua.ac.be

Competing interests None.

Provenance and peer review Commissioned; not externally peer reviewed.

Published Online First 5 October 2010

Heart 2010;96:2043—2044. doi:10.1136/hrt.2010.209997

REFERENCES


Short-term effects of transcatheter aortic valve implantation

To the Editor I read with interest the paper by Gotzmann et al in Heart1 demonstrating some very important differences after transcatheter aortic valve implantation (TAVI), particularly improvements in exercise tolerance and quality of life. I do have some reservations, however, on the statistical methodology employed. The study involved a cohort of 44 patients, assessed before and after TAVI, so clearly paired statistical tests are appropriate. However, the group chose to use the unpaired Student t, Mann—Whitney U and χ² tests, instead of the correct (and more powerful) paired Student t, Wilcoxon and McNemar tests. Use of these tests would very probably have considerably increased the significance of observed differences.

On the other hand, the paper contains at least 16 independent comparative tests, and no allowance has been made for multiple comparison. Using the crudest method of correction (the Bonferroni correction), they should have considered tests to be significant at p<0.05, but at p<0.003, which would render some of the apparent significant differences to be not significant (such as LVFE and BNP).

I would recommend that the authors re-examine their stats before making the conclusions about BNP stated in the paper; it may turn out that (using the Wilcoxon test) BNP is in fact significantly reduced after TAVI in this group of patients.

David Cunningham

Correspondence to David Cunningham, Director, Central Cardiac Audit Database (CCAD), UK; david.cunningham@ccad.nildram.co.uk

Competing interests None declared.

Provenance and peer review Not commissioned; not externally peer reviewed.

Published Online First 20 October 2010

Heart 2010;96:2044. doi:10.1136/hrt.2010.208280

REFERENCE


The Authors’ reply We gratefully acknowledge receipt of the letter by David Cunningham.1 According to the suggestions of Dr Cunningham, we re-calculated our results2 and used the appropriate statistic (paired Student t, Wilcoxon and McNemar tests): still, quality of life (MLHFAQ Score) and distance in the 6 min walk test (m) significantly improved after transcatheter aortic valve implantation (both p<0.001). In addition, levels of B-type natriuretic peptide decreased (p=0.015).

Furthermore, as the author suggests, Bonferroni correction is a suitable method to make allowance for multiple comparisons. However, our study contains only three primary study parameters (quality of life (QLHFAQ Score), distance in the 6 min walk test and level of B-type natriuretic peptide), the other 15 independent comparative tests are explorative tests. Therefore, using the Bonferroni correction for three comparative tests, we considered tests to be significant at p<0.005, but at p<0.016.

Considering all aspects, we believe that we can maintain our conclusions that transcatheter aortic valve implantation leads to a significantly clinical benefit and a reduction of neurohormonal activation in patients with severe and symptomatic aortic valve stenosis.

Michael Gotzmann, Andreas Mügge

Cardiology and Angiology, BG University-Hospital Bergmannsheil, Bochum, Germany

Correspondence to Michael Gotzmann, Bergmannsheil - Ruhr-University Bochum, Borkle-de-la-Camp-Platz 1, Bochum 44789, Germany; michael.gotzmann@web.de

Competing interests None declared.

Provenance and peer review Commissioned; not externally peer reviewed.

Published Online First 20 October 2010

Heart 2010;96:2044. doi:10.1136/hrt.2010.208298

REFERENCES


CORRECTIONS

doi:10.1136/hrt.2006.104703


DOI:10.1136/hrt.2009.187609corr1

Naruko T, Furukawa A, Yunoki K, et al. Increased expression and plasma levels of myeloperoxidase are closely related to the...
Correction

Heart 2010 96: 2044 originally published online May 8, 2007
doi: 10.1136/hrt.2006.104703

Updated information and services can be found at:
http://heart.bmj.com/content/96/24/2044.3

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Errata
An erratum has been published regarding this article. Please see next page or:
/content/96/6/471.full.pdf

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/


Corrected

Khattab AA, Hamm CW, Senges S, et al. Sirolimus-eluting stent treatment for unprotected versus protected left main coronary artery disease in widespread clinical routine: 6-month and 3-year clinical follow-up results from the prospective multicentre German Cypher Registry. Heart 2007;93:1251—5. This article was printed with an incorrect DOI. The DOI should be 10.1136/hrt.2006.104703.

Heart 2010;96:471. doi:10.1136/hrt.2007.104703corr2